- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07633704
Protective Effect of Exercise on Acute High-fat Overfeeding (HFDEXC)
June 4, 2026 updated by: Matthew Barberio, George Washington University
Metabolic flexibility is the ability to switch rapidly from one substrate (i.e.
fuel source) to another (e.g.
fats to carbohydrates) in response to ingested foods.
Worse metabolic flexibility is linked to worse metabolic outcomes, but exercise is thought to be protective against nutrient excess.
We will conduct a standard oral glucose tolerance test (OGTT) to assess insulin resistance and metabolic flexibility.
Participants will be randomized to a 24-hour hypercaloric, high-fat diet (HFD) with and without an exercise bout.
During the hypercaloric HFD, participants will eat extra calories with more calories from fat than normal, which is expected to increase insulin resistance.
After each arm of the high-fat diet, we will repeat the OGTT.
During each OGTT, expired gases will be analyzed noninvasively to determine metablic flexibility.
Insulin resistance will be determined with blood drawn during each OGTT.
By comparing metabolic flexiblity and insulin resistance before and after the normal diet and after the high-fat diet intervention, a better understanding of how insulin resistance affects metabolism and how exercise can be protective will be developed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20052
- Milken Institute School of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Males or females between the ages of 20 and 40 years
- A body mass index (BMI) of 20.0 - 29.9 kg/m2.
- Low risk for risk of injury or health complications as determined by physical activity readiness questionnaire (PARQ).
Exclusion Criteria:
- Are currently taking any antioxidant supplementation (daily multivitamin not included), prescribed non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, steroids, or probiotics.
- Are currently taking any medications for management of cholesterol, diabetes, or body weight/obesity, or are undergoing hormone therapy.
- Are unwilling or unable to comply with study procedures, at the discretion of the investigators.
- Are unwilling to have biospecimens (blood and urine) collected and stored (only blood) for future research.
- Pregnant women - A urine pregnancy test will be conducted prior to any testing procedures.
- A history of disordered eating, including anorexia nervosa, bulimia nervosa, binge eating disorder, or avoidant restrictive food intake disorder or deemed high-risk for disordered eating via questionnaire.
- A history of gastrointestinal diseases, such as galactosemia, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), Celiac disease, Crohn's disease, or lactose intolerance.
- Individuals with known allergies to wheat or gluten, milk, soy, tree nuts (e.g., almonds, walnuts, pecans), or peanuts.
- Deemed high risk for food insecurity via the Hunger Vital Sign screener.
- Have followed a ketogenic diet within the last three months or have been told to avoid a high-fat diet by a medical provider for risk of cardiovascular disease.
- Cardiorespiratory fitness (VO2max) below the 30th percentile for age and sex (measured at initial screening visit)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High Fat Overfeeding
Resting metabolic rate will be used estimate total caloric need.
We will use this estimate to create a daily target calorie intake and target fat intake for the High-Fat Diets (HFD) in the study.
During the high-fat diet, subjects will eat 80% more calories than necessary with at least 65% of the calories coming from fat for one day.
|
Caloric intake 180% of daily caloric need with 65% from fat
|
|
Experimental: High Fat Overfeeding + Exercise
On the day of High Fat Overfeeding (See High Fat Overfeeding arm description), subjects will complete a single bout of exercise.
The duration of exercise will be individualized to ~25% of daily energy needs.The intensity of exercise will be individualized to be at a low intensity in the moderate domain.
Extra foods will be provided to match energy balance across the high-fat overfeeding days
|
Caloric intake 180% of daily caloric need with 65% from fat with acute moderate exercise (energy expenditure ~25% of daily caloric need).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin Sensitivity via Oral Glucose Insulin Sensitivity Index
Time Frame: Immediately following high fat diet intervention
|
Oral Glucose Insulin Sensitivity
|
Immediately following high fat diet intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Metabolic Flexibility (Respiratory Exchange Ratio) via Indirect Calorimetry
Time Frame: Immediately following high fat diet intervention
|
Respiratory Exchange Ratio, Glucose Oxidation, Fatty Acid Oxidation
|
Immediately following high fat diet intervention
|
|
Carotid Femoral Pulse Wave velocity
Time Frame: Immediately following high fat diet intervention
|
Carotid Femoral Pulse Wave Velcoity
|
Immediately following high fat diet intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew Barberio, George Washington University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2025
Primary Completion (Actual)
April 7, 2026
Study Completion (Actual)
April 9, 2026
Study Registration Dates
First Submitted
May 11, 2026
First Submitted That Met QC Criteria
June 4, 2026
First Posted (Actual)
June 8, 2026
Study Record Updates
Last Update Posted (Actual)
June 8, 2026
Last Update Submitted That Met QC Criteria
June 4, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCR246197
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual data will be annonymized by study ID number and removed of any identifying information.
Data will be shared upon reasonable request.
IPD Sharing Time Frame
Upon publication, data will be shared upon reasonable request to the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Sensitivity/Resistance
-
Paloma Almeda-ValdésCompleted
-
Société des Produits Nestlé (SPN)CompletedInsulin Sensitivity/ResistanceSwitzerland
-
Cairo UniversityNational Police HospitalActive, not recruitingInsulin Sensitivity/ResistanceEgypt
-
University of Colorado, DenverRecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | TransgenderismUnited States
-
University of Texas, El PasoCompletedInsulin Sensitivity/ResistanceUnited States
-
Hospices Civils de LyonCisbio BioassaysCompletedInsulin ResistanceFrance
-
Centre for Addiction and Mental HealthThe Physicians' Services Incorporated FoundationRecruitingCognition | Healthy Controls | Brain Insulin SensitivityCanada
-
Amsterdam UMC, location VUmcCompletedDiabetes Mellitus, Type 2 | Insulin Sensitivity/ResistanceNetherlands
-
Garvan Institute of Medical ResearchThe University of Hong Kong; University of Sydney; The University of New South... and other collaboratorsCompletedObesity | Insulin Sensitivity/ResistanceAustralia
-
Ingredion IncorporatedUnknownFocus of the Study is Insulin SensitivityUnited States
Clinical Trials on High Fat Overfeeding
-
University of AdelaideCompletedDiabetes | Metabolic SyndromeAustralia
-
University of ExeterCompletedAssessing Muscle Amino Acid Balance
-
University of AdelaideRoyal Adelaide Hospital; University of South AustraliaTerminatedInsulin ResistanceAustralia
-
Rigshospitalet, DenmarkNovo Nordisk A/S; Augustinus FondenCompletedType 2 Diabetes Mellitus | Insulin Resistance | DyslipidemiaDenmark
-
Wageningen UniversityDutch Diabetes Research FoundationCompletedObesity | Cardiovascular Disease | Diabetes Type 2Netherlands
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Agroscope Liebefeld-Posieux Research Station ALPCompletedObesity | Nutritional InterventionSwitzerland
-
National Institute of Diabetes and Digestive and...Not yet recruitingDiabetes | Metabolic Syndrome | Healthy Volunteer | Nephrotic Syndrome | Lipodystrophy | Metabolic Associated Steatotic Liver DiseaseUnited States
-
University of Alabama at BirminghamSmartFoods, Inc.Completed
-
Maastricht University Medical CenterCompleted